research
A New Myeloma Target Produced Responses in 44%
Cevostamab activated T cells against FcRH5 in a heavily pretreated Phase I population.
Published Updated Story ID: mp-2026-07-23-016
Summary
Cevostamab activated T cells against FcRH5 in a heavily pretreated Phase I population.
Among 167 patients at the recommended monotherapy dose, 44.3% responded for a median 11.2 months. The investigational drug also caused serious adverse events, including three treatment-related deaths.
Why it matters
Cevostamab activated T cells against FcRH5 in a heavily pretreated Phase I population.
Limits and context
No additional limitation was separately recorded.
Key claims
Cevostamab activated T cells against FcRH5 in a heavily pretreated Phase I population.
Evidence: source-2026-07-23-018
Sources
- Penn Medicine via Newswise: Cevostamab Phase I myeloma resultsPenn Medicine via Newswise · secondary reporting
Corrections
No corrections have been recorded for this story.